Center for Rhinology and Allergology, Wiesbaden, Germany.
Allergy and Asthma Associates of Southern California, Mission Viejo, California, USA.
Int Arch Allergy Immunol. 2021;182(11):1026-1035. doi: 10.1159/000516417. Epub 2021 Jun 3.
Allergic rhinitis (AR) is prevalent, and many patients present with moderate-to-severe symptomatic disease. The majority of patients are not satisfied with their AR treatment, despite the use of concurrent medications. These gaps underscore the need for treatment with more effective options for moderate-to-severe AR. The authors' objective was to review systematically the efficacy and safety of MP-AzeFlu for the treatment of AR. The primary outcomes studied were nasal, ocular, and total symptoms. Other outcomes included time to onset and of AR control, quality of life, and safety. Searches of PubMed and Cochrane databases were conducted on May 14, 2020, with no date restrictions, to identify publications reporting data on MP-AzeFlu. Clinical studies of any phase were included. Studies were excluded if they were not in English, were review articles, did not discuss the safety and efficacy of MP-AzeFlu for AR symptoms. Treatment of AR with MP-AzeFlu results in effective, sustained relief of nasal and ocular symptoms, and faster onset and time to control compared with intranasal azelastine or fluticasone propionate. Long-term use of MP-AzeFlu was safe, with benefits in children, adults, and adults aged ≥65 years. Other treatment options, including fluticasone propionate and azelastine alone or the combination of intranasal corticosteroids and oral antihistamine, do not provide the same level of efficacy as MP-AzeFlu in terms of rapid and sustained relief of the entire AR symptom complex. Furthermore, MP-AzeFlu significantly improves patient quality of life. MP-AzeFlu is a currently available combination that may satisfy all these patient needs and expectations.
变应性鼻炎（AR）较为普遍，许多患者表现为中重度症状性疾病。尽管同时使用多种药物，但大多数患者对 AR 的治疗效果并不满意。这些差距突显了中重度 AR 患者需要更有效的治疗选择。作者的目的是系统地回顾 MP-AzeFlu 治疗 AR 的疗效和安全性。主要研究结果为鼻部、眼部和总症状。其他结果包括 AR 控制的开始时间和持续时间、生活质量和安全性。2020 年 5 月 14 日在 PubMed 和 Cochrane 数据库中进行了检索，没有时间限制，以确定报告 MP-AzeFlu 治疗 AR 症状数据的出版物。纳入了任何阶段的临床研究。如果研究不是英文的、是综述文章、不讨论 MP-AzeFlu 治疗 AR 症状的安全性和疗效，则将其排除在外。与鼻腔用氮卓斯汀或丙酸氟替卡松相比，MP-AzeFlu 治疗 AR 可有效且持续缓解鼻部和眼部症状，且起效更快、控制时间更早。MP-AzeFlu 的长期使用是安全的，在儿童、成人和≥65 岁的成人中均具有获益。其他治疗选择，包括丙酸氟替卡松和氮卓斯汀单独使用或鼻内皮质类固醇和口服抗组胺药的联合使用，在快速和持续缓解整个 AR 症状方面，其疗效均不如 MP-AzeFlu。此外，MP-AzeFlu 可显著改善患者的生活质量。MP-AzeFlu 是一种现有组合药物，可能满足所有这些患者的需求和期望。
